Odey Asset Management LLP Form 8.3 - Advanced Oncotherapy (9445D)
June 26 2023 - 11:35AM
UK Regulatory
TIDMAVO
RNS Number : 9445D
Odey Asset Management LLP
26 June 2023
FORM 8.3
PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY
A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1%
OR MORE
Rule 8.3 of the Takeover Code (the "Code")
1. KEY INFORMATION
(a) Full name of discloser: Odey Asset Management LLP
(b) Owner or controller of interests and short positions disclosed, if different from
1(a):
The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s),
settlor and beneficiaries must be named.
--------------------------
(c) Name of offeror/offeree in relation to whose relevant securities this form relates: Advanced Oncotherapy
Use a separate form for each offeror/offeree
--------------------------
(d) If an exempt fund manager connected with an offeror/offeree, state this and specify
identity
of offeror/offeree:
--------------------------
(e) Date position held/dealing undertaken: 23 June 2023
For an opening position disclosure, state the latest practicable date prior to the
disclosure
--------------------------
(f) In addition to the company in 1(c) above, is the discloser making disclosures in NO
respect
of any other party to the offer?
If it is a cash offer or possible cash offer, state "N/A"
--------------------------
2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE
If there are positions or rights to subscribe to disclose in
more than one class of relevant securities of the offeror or
offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for
each additional class of relevant security.
(a) Interests and short positions in the relevant securities of
the offeror or offeree to which the disclosure relates following
the dealing (if any)
Class of relevant security:
Interests Short positions
------------------- ------------------
Number % Number %
----------- ------------- ---
(1) Relevant securities owned and/or controlled: 47,473,508 8.78%
----------- ------ ------------- ---
(2) Cash-settled derivatives: N/A
----------- ------ ------------- ---
(3) Stock-settled derivatives (including options) and agreements to N/A
purchase/sell:
----------- ------ ------------- ---
TOTAL: 47,473,508 8.78%
----------- ------ ------------- ---
All interests and all short positions should be disclosed.
Details of any open stock-settled derivative positions
(including traded options), or agreements to purchase or sell
relevant securities, should be given on a Supplemental Form 8 (Open
Positions).
(b) Rights to subscribe for new securities (including directors' and other employee options)
Class of relevant security in relation to which subscription warrants
right exists:
Details, including nature of the rights concerned and relevant We hold:
percentages: * AVO WARRANT 25P 01 JUL 2026: 18,000,000
* AVO WARRANT 25P 30 MAR 2026: 8,000,000
* AVO WARRANT 25P 31 OCT 2027: 24,000,000
* AVO WARRANT 60P 25 FEB 2025: 7,500,000
----------------------------------------------------
3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE
Where there have been dealings in more than one class of
relevant securities of the offeror or offeree named in 1(c), copy
table 3(a), (b), (c) or (d) (as appropriate) for each additional
class of relevant security dealt in.
The currency of all prices and other monetary amounts should be
stated.
(a) Purchases and sales
Class of relevant security Purchase/sale Number of securities Price per unit
shares sale 1,000,000 0.025
--------------- --------------------- ---------------
(b) Cash-settled derivative transactions
Class of relevant Product description Nature of dealing Number of reference Price per unit
security e.g. CFD e.g. opening/closing a securities
long/short position,
increasing/reducing a
long/short position
(c) Stock-settled derivative transactions (including options)
(i) Writing, selling, purchasing or varying
Class of Product Writing, Number of Exercise Type Expiry date Option money
relevant description purchasing, securities price per e.g. paid/
security e.g. call selling, to which unit American, received per
option varying etc. option European unit
relates etc.
(ii) Exercise
Class of relevant Product description Exercising/ exercised Number of securities Exercise price per
security e.g. call option against unit
(d) Other dealings (including subscribing for new securities)
Class of relevant security Nature of dealing Details Price per unit (if applicable)
e.g. subscription, conversion
4. OTHER INFORMATION
(a) Indemnity and other dealing arrangements
Details of any indemnity or option arrangement, or any agreement or understanding, formal
or informal, relating to relevant securities which may be an inducement to deal or refrain
from dealing entered into by the person making the disclosure and any party to the offer or
any person acting in concert with a party to the offer:
Irrevocable commitments and letters of intent should not be included. If there are no such
agreements, arrangements or understandings, state "none"
none
(b) Agreements, arrangements or understandings relating to options or derivatives
Details of any agreement, arrangement or understanding, formal or informal, between the person
making the disclosure and any other person relating to:
(i) the voting rights of any relevant securities under any option; or
(ii) the voting rights or future acquisition or disposal of any relevant securities to which
any derivative is referenced:
If there are no such agreements, arrangements or understandings, state "none"
none
(c) Attachments
Is a Supplemental Form 8 (Open Positions) attached? NO
Date of disclosure: 26 June 2023
Contact name: Eugenie de Clauzade
--------------------
Telephone number*: 020 7208 1427
--------------------
Public disclosures under Rule 8 of the Code must be made to a
Regulatory Information Service.
The Panel's Market Surveillance Unit is available for
consultation in relation to the Code's disclosure requirements on
+44 (0)20 7638 0129.
*If the discloser is a natural person, a telephone number does
not need to be included, provided contact information has been
provided to the Panel's Market Surveillance Unit.
The Code can be viewed on the Panel's website at
www.thetakeoverpanel.org.uk .
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
RETZZGZVKVFGFZM
(END) Dow Jones Newswires
June 26, 2023 11:26 ET (15:26 GMT)
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Oct 2024 to Nov 2024
Advanced Oncotherapy (LSE:AVO)
Historical Stock Chart
From Nov 2023 to Nov 2024
